Glaukos Corp. (GKOS)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$219.98-10.83%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · GKOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 45.3% |
| Our one-year growth estimate | diamond | 38.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
GKOS — earnings miss
Dated 2026-02-17
Results of Operations and Financial Condition. On February 17, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
Why it matters: Glaukos raised its 2026 sales range after strong Q3 growth. Meeting the new range would support continued growth in its main products.
Supportive ifFull-year 2026 net sales land between $775 million and $785 million.
Worry ifFull-year 2026 net sales fall below $775 million, or the company cuts its sales range.
Why it matters: U.S. Glaucoma sales grew 47% in Q3, while management named iDose TR as a key growth driver. A drop would test that momentum.
Supportive ifQ4 U.S. Glaucoma net sales exceed $118.6 million.
Worry ifQ4 U.S. Glaucoma net sales fall below $118.6 million.
Why it matters: Corneal Health sales rose 154% in Q3. Sales above that level would show that growth continued after the record quarter.
Supportive ifQ4 Corneal Health net sales exceed $59.0 million.
Worry ifQ4 Corneal Health net sales fall below $59.0 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$137 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $404 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,839 loss on $10,000 · 28.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.